Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Research and reviews on other medications

26-10-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

15-10-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

31-08-2018 | Retinopathy | Article

Could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

24-09-2018 | Atherosclerosis | Article

Prevention of atherothrombotic events in patients with diabetes mellitus: From antithrombotic therapies to new-generation glucose-lowering drugs

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2

05-09-2018 | Anti-hypertensive medications | Article

Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials

Leiter LA et al. Diabet Med 2018. doi: 10.1111/dme.13817

30-06-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

26-06-2018 | Devices and technology | Review | Article

Technology in the management of type 1 diabetes mellitus: Current status and future prospects

Tauschmann M Hovorka R. Nat Rev Rheumatol 2018. doi: 10.1038/s41574-018-0044-y

25-06-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

23-06-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

16-06-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

16-06-2018 | Risk factors | Review | Article

Methods for measuring risk for type 2 diabetes in youth: The oral glucose tolerance test (OGTT)

Chen ME, Aguirre RS, Hannon TS. Curr Diab Rep 2018; 18: 51. doi: 10.1007/s11892-018-1023-3

15-06-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

15-06-2018 | Diet | Article

Association between dietary protein intake and type 2 diabetes varies by dietary pattern

Ke Q et al. Diabetol Metab Syndr 2018; 10: 48. doi: 10.1186/s13098-018-0350-5

14-06-2018 | Dulaglutide | Article

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicenter, open-label, randomized trial

Tuttle KR et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30104-9

11-06-2018 | Diabetic foot | Article

Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial

Park KH et al. Diabetes Res Clin Prac 20184 142: 335–344. doi: 10.1016/j.diabres.2018.06.002

08-06-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

08-06-2018 | Cardiovascular outcomes | Article

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: A 7-year follow-up study

Blanc-Bisson C et al. Cardiovasc Diabetol 2018; 17: 82. doi: 10.1186/s12933-018-0718-8

04-06-2018 | Neonatal diabetes | Article

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: An international cohort study

Bowman P et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30106-2

28-05-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

22-05-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

Next
Image Credits